Table 5.
Outcome measures by dosing group.
| Standard dosing | Model-based dosing | |
| Warfarin dosing (mg/week) | Mean (S.D./range) | Mean (S.D./range) |
| Initial dose | 35.0 (0.0/35.0–35.0) | 32.2 (9.1/17.5–59.5) |
| Stable dose | 32.6 (16.8/7.0–85.0) | 28.9 (11.5/12.0–50) |
| Mean (S.D.) | Mean (S.D.) | |
| Percent time INR in range | 41.5 (24.9) | 41.7 (25.4) |
| n(%) | n(%) | |
| Maximum INR >4.0 (number of patients) | 6 (30.0) | 6 (33.3) |
| Relative dosing success* | Mean (S.D.) | Mean (S.D.) |
| Absolute deviation (initial vs. stable) | 10.9 (10.3) | 10.3 (9.3) |
| n(%) | n(%) | |
| Superior regimen (retrospective)† | 13 (35.1) | 20 (54.1) |
*For each dosing scheme, relative dosing success is based on all 37 patients who remained on warfarin since the initial dose (whether actually assigned or hypothetical) could be computed under each scheme for all patients.
†The two dosing schemes (standard vs. model-based) were compared, retrospectively, for each individual patient to determine which scheme better matched the final stable dose.